Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMaT
NCT04310930Phase 3Recruiting
- Sponsor
- The University of Queensland
- Start
- Mar 2020
- Primary completion
- Jun 2029
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of amikacin liposome inhalation suspension, tigecycline, imipenem, cefoxitin, azithromycin in Mycobacterium abscessus pulmonary disease, sponsored by The University of Queensland. Started Mar 2020; status: recruiting.
02
Drugs
amikacin liposome inhalation suspensiontigecyclineimipenemcefoxitinazithromycin
03
Conditions
Mycobacterium abscessus pulmonary disease
Beyond the preview
Go deeper on NCT04310930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310930.